Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Bronchiectasis drug trial halted early – what we know

NCT ID NCT03696290

Disease control Sponsor: University of Dundee Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This trial tested the drug Cayston (aztreonam lysine) in adults with bronchiectasis, a chronic lung disease causing cough and infections. The goal was to see if it could safely delay or reduce lung flare-ups. However, the study was stopped early and only enrolled 34 people, so we have limited information on its benefits or risks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Aztreonam lysine (Cayston)
What this could lead to
If it works, this could point toward a treatment to reduce lung infections and hospital visits for people with bronchiectasis.
What could go wrong
The trial was terminated early with only 34 participants, so results are limited. It is unclear if the drug is effective or safe for this condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

34 people

The number who actually took part.

Started

Oct 2019

Finished

Mar 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ≥ 18 years of age * Able to give informed consent * Clinical diagnosis of Bronchiectasis * CT scan of the chest demonstrating bronchiectasis in 1 or more lobes * A history of at least 3 exacerbations in the previous 12 months * Bronchiectasis severity index score \>4 * Pseudomonas aeruginosa or other Gram-negative respiratory pathogen detected in sputum or bronchoalveolar lavage on at least 1 occasion in the previous 12 months. * A sputum sample that is culture positive for P. aeruginosa or other Gram-negative respiratory pathogens sent at the screening visit and within 28 days of randomization. Pre-specified eligible organisms include Eschericia coli, Haemophilus influenzae, Moraxella catarrhalis, Klebsiella pneumoniae, Proteus mirabilis, Serratia marcescens, Achromobacter, Enterobacter and Stenotrophomonas maltophilia Exclusion Criteria: * Participant has cystic fibrosis * Immunodeficiency requiring replacement immunoglobulin. * Active tuberculosis or nontuberculous mycobacterial infection (defined as currently under treatment, or requiring treatment in the opinion of the investigator). * Recent significant haemoptysis (a volume requiring clinical intervention, within the previous 4 weeks). * Treatment with inhaled, systemic or nebulized anti-Pseudomonal antibiotics in the 28 days prior to randomization * Oral macrolides which have been taken for a period of less than 3 months prior to the start of the trial. * Treatment of an exacerbation and receiving antibiotic treatment within 4 weeks of randomization * Primary diagnosis of COPD associated with \>20 pack years smoking history. * History of poorly controlled asthma or a history of bronchospasm with inhaled antibiotics. * Pregnant or lactating females. * Participants with FEV1 \<30% predicted value at screening. * Previous history of intolerance to Aztreonam or bronchospasm reported with any other inhaled anti-bacterial. * Glomerular filtration rate (eGFR) below 30ml/min/1.73m2 or requiring dialysis. This will be determined at screening. * Use of any investigational drugs within five times of the elimination half-life after the last trial dose or within 30 days, whichever is longer. * Unstable co-morbidities (cardiovascular disease, active malignancy) which in the opinion of the investigator would make participation in the trial not in the participants best interest. * Long term oxygen therapy * Women of child bearing age or male partners of women of child bearing age and not practicing a method of acceptable birth control (see below)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bronchiectasis adult are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bronchiectasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bronchiectasis adult

Contacts and locations

Locations

  • Aintree University Hospital

    Liverpool, United Kingdom

  • Cardiff & Vale University Local Health Board

    Cardiff, CF14 4HH, United Kingdom

  • Freeman Hospital

    Newcastle upon Tyne, NE7 7DN, United Kingdom

  • Liverpool Heart and Chest Hospital

    Liverpool, L14 3PE, United Kingdom

  • Manchester University NHS Foundation Trust - Wythenshawe Hospital

    Manchester, M13 9WL, United Kingdom

  • NHS Lanakrshire University Hospital Hairmyres

    East Kilbride, G75 8RG, United Kingdom

  • NHS Lanarkshire: University Hospital Wishaw

    Wishaw, ML2 0DP, United Kingdom

  • NHS Tayside

    Dundee, DD1 9SY, United Kingdom

  • Royal Brompton & Harefield NHS Foundation Trust

    London, United Kingdom

  • Royal Papworth hospital NHS Foundation Trust

    Cambridge, CB2 0AY, United Kingdom

  • The Princess Alexandra Hospital NHS Trust

    Harlow, United Kingdom

  • Torbay Hospital

    Torquay, Devon, TQ2 7AA, United Kingdom

  • University Hospitals of Derby and Burton NHS Foundation Trust

    Derby, United Kingdom

  • University hospital Southampton NHS Foundation Trust

    Southampton, SO16 6YD, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.